Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Oct 25;10:247. doi: 10.3389/fncel.2016.00247

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Weng, Chen, Wang, Zhuang and Behnisch.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

TREK-1 is involved in eEF2K-inhibition mediated fEPSP potentiation. (A) The graph outlines fEPSP-slopes over time under three experimental conditions (control: white circles, n = 4; 5 μM A-484954: black circles, n = 6; 100 μM Fluoxetine + 5 μM A-484954: gray circles, n = 6). The pretreatment and co-application of hippocampal slices with Fluoxetine and A-484954 significantly blocked A-484954 mediated fEPSP potentiation (p < 0.01). The resulting fEPSP slopes were similar in size as in the non-drug experiments (control: white circles). Horizontal black and gray lines indicate the A-484954 and Fluoxetine application period respectively. fEPSP traces for fluoxetine co-application experiments are shown. Scale bars: 0.5 mV/10 ms. (B) The bar graph summarizes averaged fEPSP-slope values for different experiments at the 10- and 40-min time points. Brackets enclose experimental groups with significant difference (^∗∗p < 0.01, p = 0.0024; ^∗∗∗p < 0.001, p = 0.0003).